TY - JOUR
T1 - Erythrocyte leveraged chemotherapy (ELeCt)
T2 - Nanoparticle assembly on erythrocyte surface to combat lung metastasis
AU - Zhao, Zongmin
AU - Ukidve, Anvay
AU - Gao, Yongsheng
AU - Kim, Jayoung
AU - Mitragotri, Samir
N1 - Funding Information:
This work was financially supported by Wyss Institute at Harvard University. We acknowledge funding from NIH (1R01HL143806-01).
Publisher Copyright:
© 2019 The Authors.
PY - 2019/11/13
Y1 - 2019/11/13
N2 - Despite being the mainstay of cancer treatment, chemotherapy has shown limited efficacy for the treatment of lung metastasis due to ineffective targeting and poor tumor accumulation. Here, we report a highly effective erythrocyte leveraged chemotherapy (ELeCt) platform, consisting of biodegradable drug nanoparticles assembled onto the surface of erythrocytes, to enable chemotherapy for lung metastasis treatment. The ELeCt platform significantly extended the circulation time of the drug nanoparticles and delivered 10-fold higher drug content to the lung compared with the free nanoparticles. In both the early- and late-stage melanoma lung metastasis models, the ELeCt platform enabled substantial inhibition of tumor growth that resulted in significant improvement of survival. Further, the ELeCt platform can be used to deliver numerous approved chemotherapeutic drugs. Together, the findings suggest that the ELeCt platform offers a versatile strategy to enable chemotherapy for effective lung metastasis treatment.
AB - Despite being the mainstay of cancer treatment, chemotherapy has shown limited efficacy for the treatment of lung metastasis due to ineffective targeting and poor tumor accumulation. Here, we report a highly effective erythrocyte leveraged chemotherapy (ELeCt) platform, consisting of biodegradable drug nanoparticles assembled onto the surface of erythrocytes, to enable chemotherapy for lung metastasis treatment. The ELeCt platform significantly extended the circulation time of the drug nanoparticles and delivered 10-fold higher drug content to the lung compared with the free nanoparticles. In both the early- and late-stage melanoma lung metastasis models, the ELeCt platform enabled substantial inhibition of tumor growth that resulted in significant improvement of survival. Further, the ELeCt platform can be used to deliver numerous approved chemotherapeutic drugs. Together, the findings suggest that the ELeCt platform offers a versatile strategy to enable chemotherapy for effective lung metastasis treatment.
UR - http://www.scopus.com/inward/record.url?scp=85075508217&partnerID=8YFLogxK
U2 - 10.1126/sciadv.aax9250
DO - 10.1126/sciadv.aax9250
M3 - Article
C2 - 31763454
AN - SCOPUS:85075508217
SN - 2375-2548
VL - 5
JO - Science Advances
JF - Science Advances
IS - 11
M1 - aax9250
ER -